Study of Clinical Features, Treatment, and Monitoring of Fever Illnesses in the Democratic Republic of Congo Including Use of Biomarkers and Antibiotic Guidelines to Improve Care

What this Trial Is About

Researchers are investigating febrile illnesses in the Democratic Republic of Congo DRC, focusing on their causes, clinical features, and outcomes. This study builds on the previous FIKIb2 study, which examined fever-related diseases and the use of inflammatory markers like C-reactive protein CRP to manage antibiotic use better. It aims to assess the impact of CRP testing, the WHOs AWARE antibiotic guidance, and electronic decision tools on antibiotic prescribing in primary care settings, while also strengthening research capacity and biobanking in the region. The study is observational and involves multiple centers, starting with pediatric emergency and outpatient departments. It recruits adults and children presenting with fever, collecting clinical and laboratory data at the initial visit and during a three-week follow-up. Laboratory samples are stored for further research, including blood cultures and testing for viral infections like arboviruses. The study uses systematic clinical assessment, biomarker measurement, and surveillance tools to deepen understanding and improve management of febrile illnesses. Participants will undergo blood tests for CRP, white blood cell counts, malaria detection, and other routine labs. Data on symptoms, clinical presentation, and treatment adherence are collected at enrollment and through follow-up visits on days 7, 14, and 21. Researchers will analyze antibiotic use, illness severity, hospital admissions, and outcomes, aiming to improve fever management and reduce inappropriate antibiotic use across study sites. The total participation lasts approximately three weeks with continued monitoring during this period.

Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC